Browse Category

GLP-1 Drugs News 10 September 2025 - 27 December 2025

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

New York — As of 7:56 p.m. ET on Friday, December 26, 2025, Eli Lilly and Company (NYSE: LLY) is coming off a session that left the stock hovering around $1,077.75, essentially flat on the day after a narrow trading

27 December 2025

Hims & Hers Health (HIMS) Stock Today, November 23, 2025: Price, Buyback and GLP‑1 Risks

Hims & Hers Health (NYSE: HIMS) heads into the new week as one of the market’s most closely watched telehealth and weight‑loss plays — but also one of its most volatile. After Friday’s session (21 November 2025), HIMS closed at

23 November 2025

Financial Analysis · GLP-1 Drugs · Healthcare Stocks · Investing · Stock Market

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 Receptor Agonists and Neurodegenerative Diseases in 2025 GLP-1 receptor agonists like semaglutide (Ozempic®) are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain.

10 September 2025

Alzheimer’s · GLP-1 Drugs · Medicine · Neurodegenerative Diseases · NYSE:NVO · Weight Loss

Go toTop